Hypertension is a significant public health problem and is defined as average systolic and/or diastolic blood pressure ≥95^th^ percentile for gender, age and height on at least three occasions ([@ref1]). It is considered a multifactorial disorder, but approximately 30% of cases are caused by a single genetic mutation. Hypertension is the predominant and usually the only manifestation in monogenic hypertension. Three mechanisms are recognised to explain the physiopathology of monogenic hypertension: increased sodium reabsorption leading to plasma volume expansion, excessive aldosterone synthesis, and deficiencies of enzymes that regulate adrenal steroid hormone synthesis and deactivation ([@ref2]).

Monogenic hypertension may involve: a) increased Na+ transport induced by a mineralocorticoid effect, including apparent mineralocorticoid excess (AME) syndromes, glucocorticoid-remediable aldosteronism and congenital adrenal hyperplasia due to 11β-hydroxylase or 17α-hydroxylase deficiency; or b) increased Na+ transport independent of mineralocorticoids, including Liddle's and Gordon's syndromes.

Apparent mineralocorticoid excess is a rare disorder arising from impaired activity of 11-beta-hydroxysteroid dehydrogenase type II (HSD11B2). This enzyme is responsible for converting active cortisol to inactive cortisone at aldosterone binding sites. In AME patients, the persistence of cortisol leads to increased mineralocorticoid activity due to higher cortisol affinity for the mineralocorticoid receptor. The consequences are hypokalemia, metabolic alkalosis, low plasma renin activity and low plasma aldosterone levels ([@ref3]).

Glucocorticoid-remediable aldosteronism is a rare disorder caused by unequal crossover of two adjacent genes, *CYP11B1* and *CYP11B2* (coding for 11β-hydroxylase and aldosterone synthase, respectively). The chimeric gene encodes a hybrid protein that stimulates aldosterone production, independent of renin, resulting in upregulation of Na+ reabsorption and K^+^ secretion. Although plasma renin is low, plasma concentrations of aldosterone may be normal. Patients show mild hypokalemia and metabolic alkalosis ([@ref1]).

Congenital adrenal hyperplasia presents with hypertension and may be due to deficiency of 11β-hydroxylase or 17α-hydroxylase. Excess production of steroid intermediaries with mineralocorticoid effects lead to hypernatremia, hypokalemia and low-renin HT.

Liddle syndrome (pseudo-hyperaldosteronism) is a rare disorder due to an epithelial Na^+^ channel gain of function. Enhanced epithelial Na^+^ channel activity causes increased Na^+^ reabsorption, increased intravascular volume, suppression of renin activity and reduction of aldosterone levels. Additional abnormalities include metabolic alkalosis and hypokalemia ([@ref4]). Patients respond well to K-sparing diuretics such as triamterene and amiloride, but spironolactone is ineffective for blood pressure control in patients with this syndrome.

Gordon syndrome (pseudo-hypoaldosteronism type II) is caused by gain-of-function pathogenic variants in four genes that regulate Na-K-Cl cotransporter activity in the distal convoluted tubules of the kidney, with overexpression of Na-Cl cotransporters at the apical surface of the cells, causing increased Na^+^ reabsorption ([@ref5]). Affected individuals show early-onset hyperkalemia, normal Na^+^ levels, hyperchloremia, metabolic acidosis and hypercalciuria. Plasma renin activity is suppressed and aldosterone levels are inappropriately low in relation to hyperkalemia. Thiazides are recommended to correct electrolyte abnormalities and blood pressure.

Diagnosis is based on routine physical examination, blood pressure measurement and laboratory analysis of renin, aldosterone, cortisol and potassium. Genetic testing is useful for confirming diagnosis and for differential diagnosis. Differential diagnosis should consider hypertension secondary to renal parenchymal disease, renal artery stenosis, adrenal gland neoplasia, hyperthyroidism, alcohol abuse and excessive dietary salt intake.

The estimated global age-standardized prevalence of hypertension in adults aged ≥20 years was 32.6% in the period 2009-2012. Genetic factors are thought to contribute to 30-60% of blood pressure variations, although known genetic factors explain only 3% of blood pressure variability ([@ref6]).

Monogenic hypertension has autosomal dominant or autosomal recessive inheritance ([Table 1](#T1){ref-type="table"}). Pathogenic variants may be missense, nonsense, splicing or small indels. Large deletions/duplications have also been reported in *CYP11B1, CYP11B2, NR3C2, SCNN1B, WNK1, HSD11B2, CYP17A1* and *SCNN1A*.

###### 

Genes associated with various forms of monogenic hypertension

  Gene        OMIM gene   Disease                                 OMIM disease     Inheritance   Function
  ----------- ----------- --------------------------------------- ---------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *CYP11B1*   610613      HALD1, congenital adrenal hyperplasia   103900, 202010   AD, AR        Drug metabolism, synthesis of cholesterol, steroids, other lipids
  *KLHL3*     605775      PHA2D                                   614495           AD, AR        Regulator of ion transport in the distal nephron
  *CUL3*      603136      PHA2E                                   614496           AD            Role in late endosome maturation
  *NR3C2*     600983      PHA1A                                   177735           AD            Receptor for aldosterone, corticosterone, cortisol
  *SCNN1B*    600760      LIDLS1, PHA1B                           177200, 264350   AD, AR        Essential role in electrolyte and blood pressure homeostasis
  *SCNN1G*    600761      LIDLS2, PHA1B                           618114, 264350   AD, AR        Essential role in electrolyte and blood pressure homeostasis
  *WNK1*      605232      PHA2C                                   614492           AD            Regulation of electrolyte homeostasis and cell signaling, survival, and proliferation. Activator of sodium-coupled chloride cotransporters, inhibitor of potassium-coupled chloride cotransporters
  *WNK4*      601844      PHA2B, PHA2A                            614491, 145260   AD, AR        Regulation of electrolyte homeostasis and cell signaling, survival, and proliferation. Activator of sodium-coupled chloride cotransporters, inhibitor of potassium-coupled chloride cotransporters
  *PDE3A*     123805      HTNB                                    112410           AD            Regulation of vascular smooth muscle contraction and relaxation
  *HSD11B2*   614232      AME                                     218030           AR            Conversion of cortisol to the inactive metabolite cortisone
  *CYP17A1*   609300      Congenital adrenal hyperplasia          202110           AR            Catalysis of reactions involved in drug metabolism; synthesis of cholesterol, steroids, other lipids
  *SCNN1A*    600228      PHA1B                                   264350           AR            Electrolyte and blood pressure homeostasis

AD=autosomal dominant; AR=autosomal recessive; HALD=familial hyperaldosteronism; PHA=pseudohypoaldosteronism; LIDLS=Liddle syndrome; HTNB=hypertension and brachydactyly syndrome; AME=apparent mineralocorticoid excess.

We use a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the above genes, and MLPA to detect duplications and deletions in *CYP11B1, CYP11B2, NR3C2, SCNN1B, WNK1, HSD11B2, CYP17A1* and *SCNN1A*.

Worldwide, 10 accredited medical genetic laboratories in the EU and 13 in the US, listed in the Orphanet ([@ref7]) and GTR ([@ref8]) databases, respectively, offer genetic tests for monogenic hypertension. The guidelines for clinical use of genetic testing are described in Genetics Home Reference ([@ref9]).

Conclusions {#sec1-2}
===========

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with cardiac disorders. When a suspect of hypertension is present, we perform the analysis of all the genes present in this short article. In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of ≥99% (coverage depth ≥10x).
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